Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe
  • Sandoz and Austrian government announce joint plans to drive long-term competitiveness of European production for key antibiotics in Europe
  • Planned combined investment of more than EUR 150 million would include major innovative technology development and implementation for large-scale manufacture of active ingredients for leading penicillin products
  • Kundl manufacturing site in Austria is hub of last vertically integrated antibiotics production chain in Europe; Sandoz is #1 global supplier of generic antibiotics

Holzkirchen, July 27 …

Sandoz launches generic antibiotic Daptomycin in US, strategically growing injectables portfolio and strengthening hospital offering
  • Daptomycin is an antibacterial medicine used to treat adult patients with complicated skin and skin structure infections 1
  • Daptomycin can be used to treat patients with MRSA or “superbug” infections2
  • Introduction of Daptomycin further enhances Sandoz industry-leading antibiotic portfolio, which covers 50 percent of antibiotics available worldwide

Princeton, New Jersey, July 13, 2020 — Sandoz Inc. today announced the US market introduction of Daptomycin for …

Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals
  • Sandoz to provide six injectable medicines used in acute care settings to help ensure supply reliability for optimal patient care
  • Securing reliable supply of and access to these high-quality medicines will help ensure fewer shortages and interruptions for patients requiring critical medicines
  • As a worldwide leader in generic and biosimilar medicines, Sandoz is committed to supporting efforts to deliver vital generic medicines to patients

Princeton, New Jersey, July 7, 2020 — Sandoz Inc. today announced it has …

Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
  • Sandoz evaluating next steps, including potential appeal to US Supreme Court
  • Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to making Erelzi available to US patients as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, July 1, 2020 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Court of …

Sandoz launches once-daily generic tacrolimus for transplant patients in Europe
  • Sandoz is first and only company offering complete range of dosing options in several European markets*, with 2 mg capsule allowing for fine dose titration
  • Sandoz 2 mg slow-release capsule offers simplified once-daily treatment protocol that may reduce a patient’s daily pill burden1
  • Launch builds on Sandoz experience with Adoport® — #1 twice-daily generic tacrolimus in Europe2

Holzkirchen, June 4, 2020 – Sandoz today announced the launch of once-daily generic tacrolimus capsules known as Dailiport® in …

Hungary approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 16, 2014 – Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Hungary has approved the 50- …